“The Atopic Dermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple- Atopic Dermatitis pipeline products will significantly revolutionize the Atopic Dermatitis market dynamics”
DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, Japan.
Key Takeaways from the Atopic Dermatitis Market Report
- The total prevalent cases of Atopic Dermatitis in the United States were around 32,573,900 cases in 2022.
- Approximately 60–70% of diagnosed Atopic dermatitis cases are mild, whereas ~30% are moderate-to-severe.
- The Atopic Dermatitis Companies include Sanofi/Regeneron Pharmaceuticals, Pfizer, Japan Tobacco, and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, AOBiome Therapeutics, Kymab, Qurient, Arcutis Biotherapeutics, Cara Therapeutics, Vanda Pharmaceuticals, and others.
- Promising Atopic Dermatitis Pipeline Therapies include Baricitinib, Dupilumab, Lebrikizumab, and others
Discover more about therapies set to grab major Atopic Dermatitis market share @ Atopic Dermatitis Market Size
Atopic Dermatitis Overview
Atopic dermatitis (AD), also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood but can occur at any age and can be recurrent or persistent throughout life. In ‘dermatitis,’ ‘derm’ means ‘skin,’ and ‘itis’ means ‘inflammation.’
Atopic Dermatitis Epidemiology Segmentation
- Atopic Dermatitis Prevalent Population
- Diagnosed Prevalent Population of Atopic Dermatitis
- Severity-specific Distribution of Atopic Dermatitis in Adults
- Severity-specific Distribution of Atopic Dermatitis in Pediatric Population
- Gender-specific Distribution of Atopic Dermatitis in Adults
- Chronic Pruritus Prevalence in Atopic Dermatitis in the adults
Download the report to understand which factors are driving Atopic Dermatitis epidemiology trends @ Atopic Dermatitis Epidemiological Insights
Atopic Dermatitis Emerging Drugs
- Rocatinlimab (KHK4083/AMG 451): Amgen/Kyowa Kirin
Rocatinlimab (KHK4083/AMG 451) is an anti-OX40 human monoclonal antibody that inhibits and reduces the number of OX40-expressing pathogenic T cells responsible for driving systemic and local inflammatory responses. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with Atopic Dermatitis and are critical in the disease pathophysiology. The initial antibody was discovered in collaboration between Kyowa Kirin US Research and La Jolla Institute for Immunology.
Amgen and Kyowa Kirin have recently begun recruiting participants for a comprehensive, global Phase III program (ROCKET program) to investigate the safety and efficacy of rocatinlimab in a heterogeneous moderate-to-severe AD population suffering from a high burden of disease.
Atopic Dermatitis Market Dynamics
Atopic Dermatitis market to expand because of the emergence of several novel mechanisms such as oral/topical JAK Inhibitors, PDE Inhibitors, IL-13 Inhibitors, leukotriene inhibitors, Kappa opioid receptor (KOR) agonist, NK-1 receptor antagonist, and others in the upcoming market of Atopic Dermatitis and pruritus in Atopic Dermatitis. Increased public awareness, improved access to health services, reimbursements, and financial support may boost the Atopic Dermatitis and pruritus in the market and improve the Atopic Dermatitis market accessibility of the emerging drugs.
To know more about Atopic Dermatitis Treatment options, visit @ Atopic Dermatitis Drugs
Atopic Dermatitis Marketed Drugs
- MITCHGA (nemolizumab): Chugai Pharmaceutical/Galderma/Maruho
MITCHGA (nemolizumab) was created by Chugai utilizing its proprietary antibody engineering technology called ACT-Ig, which can extend the biological half-life of antibodies in the blood. IL-31 has been identified as a pruritogenic cytokine and is reportedly involved in the generation of pruritus in Atopic Dermatitis and hemodialysis. Nemolizumab inhibits the biological activities of IL-31 by competitively blocking binding with its receptor. In early-phase clinical studies involving adults with moderate-to-severe Atopic Dermatitis, nemolizumab effectively reduced pruritus and skin signs. Currently, Galderma is conducting several trials in the US in subjects with moderate-to-severe Atopic Dermatitis.
In March 2022, Chugai Pharmaceutical announced that Maruho obtained regulatory approval from the Ministry of Health, Labour, and Welfare (MHLW) for the MITCHGA SC injection of 60 mg syringes to treat itching associated with Atopic Dermatitis. In August 2022, Chugai Pharmaceutical announced that Maruho launched MITCHGA SC injection 60 mg syringes for treating itching associated with Atopic Dermatitis.
- RINVOQ (upadacitinib): AbbVie
Upadacitinib (ABT-494) – discovered and developed by AbbVie scientists and marketed as RINVOQ – is a selective and reversible JAK inhibitor approved by the FDA and EMA in August 2019 and December 2019, respectively, for adult patients with moderately to severely active rheumatoid arthritis. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. In January 2022, AbbVie announced that the US FDA approved RINVOQ (upadacitinib) for the treatment of moderate-to-severe Atopic Dermatitis in adults and children aged 12 and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when the use of other pills or injections is not recommended.
Atopic Dermatitis Pipeline Companies
The developing pipeline of Atopic Dermatitis holds budding key players such as lebrikizumab (Eli Lilly), nemolizumab/CD14152 (Galderma), difamilast (Otsuka Pharmaceuticals), and roflumilast (Arcutis Biotherapeutics). These emerging drugs, predicted to be launched during the forecast period, are likely to change the current market dynamics of disease treatment, thereby boosting the current Atopic Dermatitis market size. Following the late-stage products, a wide array of mid-stage or Phase II promising interventions are expected to be launched soon in the Atopic Dermatitis market, including B244 (AOBiome Therapeutics), etrasimod/APD334 (Arena Pharmaceuticals), FB825 (Oneness Biotech), DS107 (DS Biopharma), bermekimab (Janssen), KY1005 (Sanofi/Kymab), and Q301 (Zileuton) (Qurient).
Learn more about the Atopic Dermatitis Pipeline Therapies in clinical trials @ New Treatment for Atopic Dermatitis
Scope of the Atopic Dermatitis Pipeline Report
- Coverage- 7MM
- Atopic Dermatitis Companies- Sanofi (NYSE: SNY), Regeneron Pharmaceuticals (NYSE: REGN), Pfizer (NYSE: PFE), Japan Tobacco, Torii Pharmaceutical (NYSE: TRXPF), Eli Lilly and Company (NYSE: LLY), AbbVie (NYSE: ABBV), LEO Pharma, Incyte Corporation (NYSE: INCY), Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen (NYSE: JNJ), AOBiome Therapeutics, Kymab, Qurient (NYSE: KRX), Arcutis Biotherapeutics (NYSE: ARQT), Cara Therapeutics (NYSE: CARA), Vanda Pharmaceuticals (NYSE: VNDA), and others.
- Atopic Dermatitis Pipeline Therapies include Baricitinib, Dupilumab, Lebrikizumab, and others.
- Atopic Dermatitis Market Dynamics: Atopic Dermatitis Market Drivers and Barriers
Discover more about Atopic Dermatitis Drugs in development @ Atopic Dermatitis Ongoing Clinical Trials Analysis
Table of Content
- Key Insights
- Atopic Dermatitis Report Introduction
- Atopic Dermatitis (AD) Market Overview at a Glance
- Epidemiology and Market Methodology
- Executive Summary
- Atopic Dermatitis Disease Background and Overview
- Atopic Dermatitis Epidemiology and Patient Population
- Patient Journey
- Key Endpoints in Atopic Dermatitis Clinical Trials
- Atopic Dermatitis Marketed Therapies
- Atopic Dermatitis Emerging Therapies
- Atopic Dermatitis (Atopic Dermatitis): The 7MM Analysis
- Atopic Dermatitis Market Access and Reimbursement
- Atopic Dermatitis KOL Views
- Atopic Dermatitis SWOT Analysis
- Atopic Dermatitis Unmet Needs
- Appendix
- DelveInsight Capabilities
- Disclaimer
Get in touch with our Business executive @ Atopic Dermatitis Market Research Report
Top Selling Market Research Reports in 2023
AIDS Related Kaposi’s Sarcoma Market |AL Amyloidosis Market | Abdominal Aortic Aneurysm Market | X-Linked Retinitis Pigmentosa Market | Wiskott-aldrich Syndrome Market | Urology Ultrasounds Devices Market | Uncomplicated Urinary Tract Infection Market | Tropical Spastic Paraparesis Market | Systemic Sclerosis-associated Interstitial Lung Disease Market | Spondylolisthesis Market
Latest Blogs By DelveInsight
Trending Report
Concussions Market Size | Pruritus Market | Angioedema Market | Blood Gas And Electrolyte Analyzers Market | Human Papilomavirus Market | Neurovascular Devices Market | Pain Management Devices Market | Pressure Ulcers Market Size | Acute Coronary Syndrome Market | Apheresis Market | Arteriotomy Closure Devices Market | Automated External Defibrillators Market | Xerostomia Market | Choroidal Neovascularization Market | Hyperhidrosis Market | Alopecia Market | Contraceptive Devices Market | Ventilator Market | Alopecia Aerata Market | Osteoarthritis Market | Neurostimulation Devices Market | Global Electrophysiology Devices Market | Astigmatism Market | Graves Orbitopathy Market | HPV-Induced Cancers Market | Hypothalamic Obesity Market | Italy healthcare outlook report
Consulting Services:
Biotech Consulting | Business Consulting Services | Consulting Services | Healthcare Business Development | Healthcare Consulting Services | Healthcare Strategy Consulting | Life Science Consulting | Life Science Consulting Firms
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com